首页 > 最新文献

BioResearch Open Access最新文献

英文 中文
Regulation of Myogenic Activity by Substrate and Electrical Stimulation In Vitro 底物和电刺激对体外肌生成活性的调节
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-07-30 DOI: 10.1089/biores.2019.0016
Anjali Patel, Sara Vendrell-Gonzalez, G. Haas, M. Marcinczyk, Natalia Ziemkiewicz, Muhamed Talovic, J. Fisher, K. Garg
Abstract Skeletal muscle has a remarkable regenerative capacity in response to mild injury. However, when muscle is severely injured, muscle regeneration is impaired due to the loss of muscle-resident stem cells, known as satellite cells. Fibrotic tissue, primarily comprising collagen I (COL), is deposited with this critical loss of muscle. In recent studies, supplementation of laminin (LM)-111 has been shown to improve skeletal muscle regeneration in several models of disease and injury. Additionally, electrical stimulation (E-stim) has been investigated as a possible rehabilitation therapy to improve muscle's functional recovery. This study investigated the role of E-stim and substrate in regulating myogenic response. C2C12 myoblasts were allowed to differentiate into myotubes on COL- and LM-coated polydimethylsiloxane molds. The myotubes were subjected to E-stim and compared with nonstimulated controls. While E-stim resulted in increased myogenic activity, irrespective of substrate, LM supported increased proliferation and uniform distribution of C2C12 myoblasts. In addition, C2C12 myoblasts cultured on LM showed higher Sirtuin 1, mammalian target of rapamycin, desmin, nitric oxide, and vascular endothelial growth factor expression. Taken together, these results suggest that an LM substrate is more conducive to myoblast growth and differentiation in response to E-stim in vitro.
摘要骨骼肌在轻度损伤后具有显著的再生能力。然而,当肌肉受到严重损伤时,肌肉再生会因肌肉常驻干细胞(即卫星细胞)的丧失而受损。纤维化组织主要由胶原I (COL)组成,随着肌肉的严重损失而沉积。在最近的研究中,补充层粘连蛋白(LM)-111已被证明可以改善几种疾病和损伤模型中的骨骼肌再生。此外,电刺激(E-stim)已被研究作为一种可能的康复治疗,以改善肌肉的功能恢复。本研究探讨了E-stim和底物在调节肌生成反应中的作用。C2C12成肌细胞在COL和lm包被的聚二甲基硅氧烷霉菌上分化成肌管。肌管受到电刺激,并与未受刺激的对照组进行比较。与底物无关,E-stim增加了成肌活性,LM增加了C2C12成肌细胞的增殖和均匀分布。此外,在LM上培养的C2C12成肌细胞Sirtuin 1、哺乳动物雷帕霉素靶蛋白、desmin、一氧化氮和血管内皮生长因子的表达均较高。综上所述,这些结果表明,LM底物在体外对E-stim的反应中更有利于成肌细胞的生长和分化。
{"title":"Regulation of Myogenic Activity by Substrate and Electrical Stimulation In Vitro","authors":"Anjali Patel, Sara Vendrell-Gonzalez, G. Haas, M. Marcinczyk, Natalia Ziemkiewicz, Muhamed Talovic, J. Fisher, K. Garg","doi":"10.1089/biores.2019.0016","DOIUrl":"https://doi.org/10.1089/biores.2019.0016","url":null,"abstract":"Abstract Skeletal muscle has a remarkable regenerative capacity in response to mild injury. However, when muscle is severely injured, muscle regeneration is impaired due to the loss of muscle-resident stem cells, known as satellite cells. Fibrotic tissue, primarily comprising collagen I (COL), is deposited with this critical loss of muscle. In recent studies, supplementation of laminin (LM)-111 has been shown to improve skeletal muscle regeneration in several models of disease and injury. Additionally, electrical stimulation (E-stim) has been investigated as a possible rehabilitation therapy to improve muscle's functional recovery. This study investigated the role of E-stim and substrate in regulating myogenic response. C2C12 myoblasts were allowed to differentiate into myotubes on COL- and LM-coated polydimethylsiloxane molds. The myotubes were subjected to E-stim and compared with nonstimulated controls. While E-stim resulted in increased myogenic activity, irrespective of substrate, LM supported increased proliferation and uniform distribution of C2C12 myoblasts. In addition, C2C12 myoblasts cultured on LM showed higher Sirtuin 1, mammalian target of rapamycin, desmin, nitric oxide, and vascular endothelial growth factor expression. Taken together, these results suggest that an LM substrate is more conducive to myoblast growth and differentiation in response to E-stim in vitro.","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90498587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Will Women Interact with Technology to Understand Their Cardiovascular Risk and Potentially Increase Activity? 女性是否会通过与科技互动来了解自己的心血管风险并增加活动量?
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-07-03 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2018.0047
Kathy Hildebrand, Kathryn King-Shier, Lorraine Venturato, Christy Tompkins-Lane

Cardiovascular disease (CVD) continues to be one of the leading causes of death for women. New approaches need to be identified that will enable women to recognize modifiable risk factors and target their efforts toward prevention. The objectives of this study were to (1) determine if women would access Vivametrica to assess CVD risk, (2) identify whether women would increase their physical activity as measured by their daily step counts, and (3) elicit women's opinions about using the system, prospective observational study design. Thirty-six English-speaking women aged 45-64 years of age, without physical disability, were recruited. Participants attended two clinic visits and were asked to wear a sensor-based activity monitor (Garmin Vivosmart® HR Wrist Tracker) for 12 weeks. Twenty-six (72%) of participants accessed Vivametrica for the course of the study. The median number of steps at baseline and at study completion was 9329 (range 5406-18,228) and 10,181 (range 5398-21,401), respectively. There was no significant change in number of steps taken by the participants for the study period (Z = -1.086, p = 0.278). The women's responses to the three statements (related to using Vivametrica) are represented on bar graphs. Women's opinions were important to provide an understanding about how they realized the technology. Women did access Vivametrica. Women did not significantly increase their step count. However, these women were achieving beyond sedentary levels of activity (>5000 steps/day). Although the change in steps was not statistically significant, it represents a median increase in daily steps of 9%, which is clinically important.

心血管疾病(CVD)仍然是导致女性死亡的主要原因之一。需要确定新的方法,使妇女能够识别可改变的风险因素,并有针对性地进行预防。本研究的目标是:(1)确定妇女是否会使用 Vivametrica™ 评估心血管疾病风险;(2)确定妇女是否会增加以每日步数为衡量标准的体育锻炼;以及(3)征求妇女对使用该系统的意见。研究人员招募了 36 名讲英语的女性,年龄在 45-64 岁之间,无身体残疾。参与者接受了两次门诊,并被要求佩戴传感器式活动监测器(Garmin Vivosmart® HR 腕式追踪器)12 周。26名参与者(72%)在研究过程中使用了Vivametrica。基线和研究完成时的步数中位数分别为 9329 步(范围为 5406-18228 步)和 10181 步(范围为 5398-21401 步)。在研究期间,参与者的步数没有明显变化(Z = -1.086, p = 0.278)。妇女对三项陈述(与使用 Vivametrica 有关)的答复以柱状图表示。妇女的意见对于了解她们如何使用该技术非常重要。妇女确实使用了 Vivametrica。妇女的步数没有明显增加。但是,这些妇女的活动量超过了久坐不动的水平(>5000 步/天)。虽然步数的变化在统计学上并不显著,但它代表着每天步数增加的中位数为 9%,这在临床上具有重要意义。
{"title":"Will Women Interact with Technology to Understand Their Cardiovascular Risk and Potentially Increase Activity?","authors":"Kathy Hildebrand, Kathryn King-Shier, Lorraine Venturato, Christy Tompkins-Lane","doi":"10.1089/biores.2018.0047","DOIUrl":"10.1089/biores.2018.0047","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) continues to be one of the leading causes of death for women. New approaches need to be identified that will enable women to recognize modifiable risk factors and target their efforts toward prevention. The objectives of this study were to (1) determine if women would access Vivametrica<sup>™</sup> to assess CVD risk, (2) identify whether women would increase their physical activity as measured by their daily step counts, and (3) elicit women's opinions about using the system, prospective observational study design. Thirty-six English-speaking women aged 45-64 years of age, without physical disability, were recruited. Participants attended two clinic visits and were asked to wear a sensor-based activity monitor (Garmin Vivosmart<sup>®</sup> HR Wrist Tracker) for 12 weeks. Twenty-six (72%) of participants accessed Vivametrica for the course of the study. The median number of steps at baseline and at study completion was 9329 (range 5406-18,228) and 10,181 (range 5398-21,401), respectively. There was no significant change in number of steps taken by the participants for the study period (Z = -1.086, <i>p</i> = 0.278). The women's responses to the three statements (related to using Vivametrica) are represented on bar graphs. Women's opinions were important to provide an understanding about how they realized the technology. Women did access Vivametrica. Women did not significantly increase their step count. However, these women were achieving beyond sedentary levels of activity (>5000 steps/day). Although the change in steps was not statistically significant, it represents a median increase in daily steps of 9%, which is clinically important.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37392380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Alliance in a Single Versus Group Rehabilitative Setting After Breast Cancer Surgery: Psychological Profile and Performance Rehabilitation. 乳腺癌术后单人与集体康复环境中的治疗联盟:心理状况与康复表现
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-07-03 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2019.0011
Teresa Paolucci, Andrea Bernetti, Marco Paoloni, Serena V Capobianco, Arianna V Bai, Carlo Lai, Laura Pierro, Monica Rotundi, Carlo Damiani, Valter Santilli, Francesco Agostini, Massimiliano Mangone

The survival rate of women after breast cancer has improved significantly worldwide. More attention should be paid to the rehabilitation intervention after surgery. Cancer rehabilitation helps breast cancer survivors maintain the highest possible physical, social, psychological, and vocational function in the limits that are imposed by the cancer and its treatments. The aim of our research was to determine the rehabilitative setting that promotes greater efficacy of the rehabilitation. A double-blind, randomized controlled trial with 45 patients enrolled was conducted. All participants were randomized into two groups: single rehabilitative training (N = 22) and group rehabilitative training (N = 23). Outcomes were assessed for each group before treatment (T0), after first 6 weeks of rehabilitative treatment (T1), and after 3 months (T2). All patients underwent the same rehabilitation treatment, but the setting differed between single and group rehabilitative training, which included four to five patients each and evaluated using Minnesota Multiphasic Personality Inventory (MMPI-2), Working Alliance Inventory Patient form (WAIP), Disabilities of Arm, Shoulder and Hand Questionnaire (DASH), and visual analog scale (VAS). Two patients dropped out in the single treatment group. In the within-group analysis at the three evaluation times, on the VAS, a significant reduction in pain was reported and maintained at the follow-up, as was observed for the DASH and WAIP scales. In the between-group analysis WAIP and Bond scale scores differed significantly in favor of the single treatment. In the group treatment, the Psychopathic Deviate, Masculine/Feminine, and Social Discomfort scales of the MMPI-2 correlated with WAIP Tot at T1. There was an association between the Correction, Hysteria, Paranoid, and Schizophrenia MMPI-2 scales and Δ VAS T0T1 in the total sample. Proposing the same rehabilitative intervention in both breast cancer groups, our results showed significant reduction in pain and good functional recovery of the upper limb, which did not depend on the setting (single or group). However, with single rehabilitation treatment, patients developed a better therapeutic alliance and experienced a more comfortable environment.

全世界妇女乳腺癌术后的存活率已大幅提高。术后康复干预应得到更多关注。癌症康复有助于乳腺癌幸存者在癌症及其治疗所带来的限制下,保持尽可能高的身体、社交、心理和职业功能。我们的研究目的是确定能提高康复效果的康复环境。我们进行了一项双盲随机对照试验,共有 45 名患者参加。所有参与者被随机分为两组:单一康复训练组(22 人)和小组康复训练组(23 人)。每组患者在治疗前(T0)、康复治疗头 6 周后(T1)和 3 个月后(T2)进行疗效评估。所有患者都接受了相同的康复治疗,但单人康复训练和小组康复训练的环境不同,每组包括四至五名患者,使用明尼苏达多相人格量表(MMPI-2)、工作联盟量表患者表(WAIP)、手臂、肩部和手部残疾问卷(DASH)以及视觉模拟量表(VAS)进行评估。单一治疗组中有两名患者退出。在三次评估的组内分析中,视觉模拟量表显示疼痛明显减轻,并在随访中保持不变,DASH 和 WAIP 量表也是如此。在组间分析中,WAIP 量表和 Bond 量表得分的显著差异有利于单一疗法。在小组治疗中,MMPI-2 的精神病性偏差、男性/女性和社交不适量表与 T1 期的 WAIP Tot 存在相关性。在所有样本中,MMPI-2 的矫正、癔症、偏执和精神分裂量表与 T0T1 的 Δ VAS 之间存在关联。我们建议对两组乳腺癌患者采取相同的康复干预措施,结果显示疼痛明显减轻,上肢功能恢复良好,这与康复环境(单人或集体)无关。然而,在单一康复治疗中,患者建立了更好的治疗联盟,体验了更舒适的环境。
{"title":"Therapeutic Alliance in a Single Versus Group Rehabilitative Setting After Breast Cancer Surgery: Psychological Profile and Performance Rehabilitation.","authors":"Teresa Paolucci, Andrea Bernetti, Marco Paoloni, Serena V Capobianco, Arianna V Bai, Carlo Lai, Laura Pierro, Monica Rotundi, Carlo Damiani, Valter Santilli, Francesco Agostini, Massimiliano Mangone","doi":"10.1089/biores.2019.0011","DOIUrl":"10.1089/biores.2019.0011","url":null,"abstract":"<p><p>The survival rate of women after breast cancer has improved significantly worldwide. More attention should be paid to the rehabilitation intervention after surgery. Cancer rehabilitation helps breast cancer survivors maintain the highest possible physical, social, psychological, and vocational function in the limits that are imposed by the cancer and its treatments. The aim of our research was to determine the rehabilitative setting that promotes greater efficacy of the rehabilitation. A double-blind, randomized controlled trial with 45 patients enrolled was conducted. All participants were randomized into two groups: single rehabilitative training (<i>N</i> = 22) and group rehabilitative training (<i>N</i> = 23). Outcomes were assessed for each group before treatment (T0), after first 6 weeks of rehabilitative treatment (T1), and after 3 months (T2). All patients underwent the same rehabilitation treatment, but the setting differed between single and group rehabilitative training, which included four to five patients each and evaluated using Minnesota Multiphasic Personality Inventory (MMPI-2), Working Alliance Inventory Patient form (WAIP), Disabilities of Arm, Shoulder and Hand Questionnaire (DASH), and visual analog scale (VAS). Two patients dropped out in the single treatment group. In the within-group analysis at the three evaluation times, on the VAS, a significant reduction in pain was reported and maintained at the follow-up, as was observed for the DASH and WAIP scales. In the between-group analysis WAIP and Bond scale scores differed significantly in favor of the single treatment. In the group treatment, the Psychopathic Deviate, Masculine/Feminine, and Social Discomfort scales of the MMPI-2 correlated with WAIP Tot at T1. There was an association between the Correction, Hysteria, Paranoid, and Schizophrenia MMPI-2 scales and Δ VAS T0T1 in the total sample. Proposing the same rehabilitative intervention in both breast cancer groups, our results showed significant reduction in pain and good functional recovery of the upper limb, which did not depend on the setting (single or group). However, with single rehabilitation treatment, patients developed a better therapeutic alliance and experienced a more comfortable environment.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37392381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyper-Crosslinked Carbohydrate Polymer for Repair of Critical-Sized Bone Defects 超交联碳水化合物聚合物修复临界尺寸骨缺损
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-07-01 DOI: 10.1089/biores.2019.0021
Plamena M. Koleva, James H. Keefer, Alexandria M. Ayala, Isabela Lorenzo, C. E. Han, Kristen Pham, Stacy E. Ralston, Kee D. Kim, Charles C. Lee
Abstract This study evaluated the safety and efficacy of a novel hyper-crosslinked carbohydrate polymer (HCCP) for the repair of critical-sized bone defects in comparison to two alternative treatments: autologous bone and poly(lactide-co-glycolide) with hyaluronic acid (PLGA/HA). Bilateral critical-sized defects were created in the lateral femoral condyles of skeletally mature New Zealand White rabbits, and they were subsequently implanted with HCCP, PLGA/HA, or autologous bone in a randomized manner. Clinical and behavioral observations were made daily, and radiological and histopathological evaluations were performed at 4, 10, and 16 weeks postimplantation. Defects implanted with HCCP showed progressive bone regeneration and bridging of the defect without adverse histological events. No signs of infection or inflammation associated with the implant material were observed in all animals that received HCCP implantation. A radiographic assessment performed at 16 weeks post-implantation showed significantly higher bone density and volume in defects implanted with HCCP compared to PLGA/HA. No statistically significant difference was observed in bone density and volume between HCCP and autologous bone. These findings demonstrate that HCCP is biocompatible, osteoconductive, and capable of promoting bone regeneration in vivo; therefore, it is suitable for both tissue engineering and the repair of critical-sized bone defects.
摘要:本研究评估了一种新型超交联碳水化合物聚合物(HCCP)用于修复临界尺寸骨缺损的安全性和有效性,并与两种替代治疗方法进行了比较:自体骨和透明质酸(PLGA/HA)聚乳酸-羟基乙酸酯。在骨骼成熟的新西兰大白兔股骨外侧髁上制造双侧临界大小的缺损,随后随机植入HCCP、PLGA/HA或自体骨。每天进行临床和行为观察,并于植入后4周、10周和16周进行放射学和组织病理学评估。骨缺损植入HCCP后,骨再生和骨桥逐渐愈合,无不良组织学事件发生。在所有接受HCCP植入的动物中,没有观察到与植入材料相关的感染或炎症迹象。植入16周后进行的x线评估显示,与PLGA/HA相比,HCCP植入缺陷的骨密度和体积明显更高。HCCP与自体骨在骨密度和体积上无统计学差异。这些研究结果表明,HCCP具有生物相容性、骨导电性和促进骨再生的能力;因此,它既适用于组织工程,也适用于临界尺寸骨缺损的修复。
{"title":"Hyper-Crosslinked Carbohydrate Polymer for Repair of Critical-Sized Bone Defects","authors":"Plamena M. Koleva, James H. Keefer, Alexandria M. Ayala, Isabela Lorenzo, C. E. Han, Kristen Pham, Stacy E. Ralston, Kee D. Kim, Charles C. Lee","doi":"10.1089/biores.2019.0021","DOIUrl":"https://doi.org/10.1089/biores.2019.0021","url":null,"abstract":"Abstract This study evaluated the safety and efficacy of a novel hyper-crosslinked carbohydrate polymer (HCCP) for the repair of critical-sized bone defects in comparison to two alternative treatments: autologous bone and poly(lactide-co-glycolide) with hyaluronic acid (PLGA/HA). Bilateral critical-sized defects were created in the lateral femoral condyles of skeletally mature New Zealand White rabbits, and they were subsequently implanted with HCCP, PLGA/HA, or autologous bone in a randomized manner. Clinical and behavioral observations were made daily, and radiological and histopathological evaluations were performed at 4, 10, and 16 weeks postimplantation. Defects implanted with HCCP showed progressive bone regeneration and bridging of the defect without adverse histological events. No signs of infection or inflammation associated with the implant material were observed in all animals that received HCCP implantation. A radiographic assessment performed at 16 weeks post-implantation showed significantly higher bone density and volume in defects implanted with HCCP compared to PLGA/HA. No statistically significant difference was observed in bone density and volume between HCCP and autologous bone. These findings demonstrate that HCCP is biocompatible, osteoconductive, and capable of promoting bone regeneration in vivo; therefore, it is suitable for both tissue engineering and the repair of critical-sized bone defects.","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77524423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
How Health Care Providers Can Use Digital Health Technologies to Inform Human Papillomavirus (HPV) Decision Making and Promote the HPV Vaccine Uptake Among Adolescents and Young Adults. 卫生保健提供者如何利用数字卫生技术为人乳头瘤病毒(HPV)决策提供信息,并促进青少年和年轻人接种HPV疫苗。
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-06-10 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2018.0051
Versie Johnson-Mallard, Gabrielle Darville, Rebeccah Mercado, Charkarra Anderson-Lewis, Jann MacInnes

High-risk stains of human papillomavirus (HPV) is linked to causing cancer, is highly prevalent, and has increased incidence among adolescents and young adults. However, vaccination rates are low. Health care provider recommendation is the biggest influencer toward vaccine uptake. Since more health care providers are using digital health technologies in their medical practices, this study investigated the feasibility of technology to increase informed decision making. A convenience sample of 210 students completed an online survey. Participants were 18-25 years of age (88%), female (85%), Caucasian (60%), and never been diagnosed with HPV (92.9%). Overwhelmingly, participants owned a smartphone (98.9%) and used mobile apps for health/health tracking (65.5%). However, only 29.3% indicated that they received text messages from their health care provider. Digital health technology can be a cost-effective way for increasing HPV knowledge, removing barriers, and increasing vaccine uptake. Health care providers should explore using various platforms to empower their health care decision making.

人类乳头瘤病毒(HPV)的高风险染色与致癌有关,非常普遍,在青少年和年轻人中发病率增加。然而,疫苗接种率很低。卫生保健提供者的建议是对疫苗接种影响最大的因素。由于越来越多的卫生保健提供者在其医疗实践中使用数字卫生技术,本研究调查了技术增加知情决策的可行性。210名学生方便地完成了一项在线调查。参与者年龄为18-25岁(88%),女性(85%),高加索人(60%),从未被诊断为HPV(92.9%)。绝大多数参与者拥有智能手机(98.9%),并使用移动应用程序进行健康/健康跟踪(65.5%)。然而,只有29.3%的人表示他们收到了医疗保健提供者的短信。数字卫生技术可以成为提高人乳头瘤病毒知识、消除障碍和提高疫苗吸收率的一种经济有效的方式。卫生保健提供者应探索使用各种平台来增强其卫生保健决策的能力。
{"title":"How Health Care Providers Can Use Digital Health Technologies to Inform Human Papillomavirus (HPV) Decision Making and Promote the HPV Vaccine Uptake Among Adolescents and Young Adults.","authors":"Versie Johnson-Mallard,&nbsp;Gabrielle Darville,&nbsp;Rebeccah Mercado,&nbsp;Charkarra Anderson-Lewis,&nbsp;Jann MacInnes","doi":"10.1089/biores.2018.0051","DOIUrl":"https://doi.org/10.1089/biores.2018.0051","url":null,"abstract":"<p><p>High-risk stains of human papillomavirus (HPV) is linked to causing cancer, is highly prevalent, and has increased incidence among adolescents and young adults. However, vaccination rates are low. Health care provider recommendation is the biggest influencer toward vaccine uptake. Since more health care providers are using digital health technologies in their medical practices, this study investigated the feasibility of technology to increase informed decision making. A convenience sample of 210 students completed an online survey. Participants were 18-25 years of age (88%), female (85%), Caucasian (60%), and never been diagnosed with HPV (92.9%). Overwhelmingly, participants owned a smartphone (98.9%) and used mobile apps for health/health tracking (65.5%). However, only 29.3% indicated that they received text messages from their health care provider. Digital health technology can be a cost-effective way for increasing HPV knowledge, removing barriers, and increasing vaccine uptake. Health care providers should explore using various platforms to empower their health care decision making.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/biores.2018.0051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37076597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
The Effect of Calcium and Glucose Concentration on Corneal Epithelial Cell Lines Differentiation, Proliferation, and Focal Adhesion Expression. 钙和葡萄糖浓度对角膜上皮细胞系分化、增殖和局灶黏附表达的影响。
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-06-05 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2018.0036
Sophia Masterton, Mark Ahearne

It is known that culture media composition can affect cell behavior, morphology, and gene expression. However, in the case of corneal epithelial cells, the combined role of calcium and glucose concentration in media has not previously been examined. In this study, a human immortalized corneal epithelial cell line was used to examine the effect of glucose and calcium concentrations on these cells. Cell metabolic activity, cell growth curve analysis, and relative gene and protein expression of proliferative marker extracellular related kinase (ERK) were used to study proliferation. Corneal epithelial stem cell marker NP63 and mature epithelial marker cytokeratin 3 (CK3) were analyzed by using reverse transcription polymerase chain reaction (RT-PCR) and immunocytochemistry. Focal adhesions were examined by using immunocytochemistry. Cells cultured in both low-glucose, high-calcium (LG-HC) media and high-glucose, low-calcium (HG-LC) media showed similar results in both RT-PCR and immunocytochemistry analysis. NP63 expression was significantly lower and CK3 expression was higher in these groups compared with cells cultured in commercial media. NP63 and CK3 expression was also analyzed by using immunocytochemistry, which confirmed these findings. The high-glucose, high-calcium-fed cells showed the lowest expression of all markers and no gene expression of CK3. This was deemed the most unsuitable media formulation for this cell line. Focal adhesion expression was the lowest in the high-calcium, high-glucose-fed cells, with the most even distribution of this among the commercial media group. Overall, this study showed that varying glucose and calcium concentrations can have significant effects on differentiation, proliferation, focal adhesions, and metabolic activity of this cell line. It seems that an LG-HC and HG-LC formulation were interchangeable with similar proliferative and differentiation effects.

众所周知,培养基成分可以影响细胞行为、形态和基因表达。然而,在角膜上皮细胞的情况下,培养基中钙和葡萄糖浓度的联合作用以前没有被研究过。在这项研究中,我们用一个人永生化角膜上皮细胞系来研究葡萄糖和钙浓度对这些细胞的影响。通过细胞代谢活性、细胞生长曲线分析和增殖标志物细胞外相关激酶(ERK)相关基因和蛋白表达来研究细胞增殖。采用逆转录聚合酶链反应(RT-PCR)和免疫细胞化学方法对角膜上皮干细胞标志物NP63和成熟上皮标志物细胞角蛋白3 (CK3)进行分析。免疫细胞化学检测局灶性粘连。在低糖高钙(LG-HC)培养基和高糖低钙(HG-LC)培养基中培养的细胞在RT-PCR和免疫细胞化学分析中显示相似的结果。与商业培养基中培养的细胞相比,NP63的表达显著降低,CK3的表达显著升高。通过免疫细胞化学分析NP63和CK3的表达,证实了上述发现。高糖、高钙喂养的细胞各项标志物表达最低,CK3基因无表达。这被认为是最不适合这个细胞系的培养基配方。高钙、高糖喂养的细胞局灶黏附表达最低,商业培养基组的局灶黏附表达最均匀。总之,本研究表明,不同的葡萄糖和钙浓度对该细胞系的分化、增殖、局灶黏附和代谢活性有显著影响。LG-HC和HG-LC制剂可互换使用,具有相似的增殖和分化作用。
{"title":"The Effect of Calcium and Glucose Concentration on Corneal Epithelial Cell Lines Differentiation, Proliferation, and Focal Adhesion Expression.","authors":"Sophia Masterton,&nbsp;Mark Ahearne","doi":"10.1089/biores.2018.0036","DOIUrl":"https://doi.org/10.1089/biores.2018.0036","url":null,"abstract":"<p><p>It is known that culture media composition can affect cell behavior, morphology, and gene expression. However, in the case of corneal epithelial cells, the combined role of calcium and glucose concentration in media has not previously been examined. In this study, a human immortalized corneal epithelial cell line was used to examine the effect of glucose and calcium concentrations on these cells. Cell metabolic activity, cell growth curve analysis, and relative gene and protein expression of proliferative marker extracellular related kinase (ERK) were used to study proliferation. Corneal epithelial stem cell marker NP63 and mature epithelial marker cytokeratin 3 (CK3) were analyzed by using reverse transcription polymerase chain reaction (RT-PCR) and immunocytochemistry. Focal adhesions were examined by using immunocytochemistry. Cells cultured in both low-glucose, high-calcium (LG-HC) media and high-glucose, low-calcium (HG-LC) media showed similar results in both RT-PCR and immunocytochemistry analysis. NP63 expression was significantly lower and CK3 expression was higher in these groups compared with cells cultured in commercial media. NP63 and CK3 expression was also analyzed by using immunocytochemistry, which confirmed these findings. The high-glucose, high-calcium-fed cells showed the lowest expression of all markers and no gene expression of CK3. This was deemed the most unsuitable media formulation for this cell line. Focal adhesion expression was the lowest in the high-calcium, high-glucose-fed cells, with the most even distribution of this among the commercial media group. Overall, this study showed that varying glucose and calcium concentrations can have significant effects on differentiation, proliferation, focal adhesions, and metabolic activity of this cell line. It seems that an LG-HC and HG-LC formulation were interchangeable with similar proliferative and differentiation effects.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/biores.2018.0036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37313560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Acceptability of Human Papillomavirus Self-Sampling Among a National Sample of Women in the United States. 人乳头瘤病毒自我抽样在美国全国妇女样本中的可接受性
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-04-30 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2018.0040
Erin Bishop, Mira L Katz, Paul L Reiter

As human papillomavirus (HPV) self-sampling continues to emerge as a potential cervical cancer screening strategy in the United States, it is necessary to examine women's acceptability of this screening approach. Furthermore, since several HPV self-sampling devices exist, it is important to determine if women's preferences differ by device type. We conducted an online survey in Fall 2017 with a national sample of women (n = 605) ages 21-65 years (the recommended age range for cervical cancer screening). Multivariable linear regression identified correlates of women's willingness to use an HPV self-sample at home. We used repeated measures analysis of variance to determine if preferences differed across four self-sampling devices: Evalyn® Brush (Device A), HerSwab® (Device B), Catch-All® Swab (Device C), and Qvintip® (Device D). Most women were willing to use an HPV self-sample at home (mean = 4.03 [possible range: 1-5], standard deviation = 1.09, 72.7% indicated "probably willing" or "definitely willing"). The most common concerns about self-sampling were related to test accuracy (53.1%) and obtaining the sample incorrectly (51.1%). Women were more willing to use an HPV self-sample at home if they reported greater perceived severity of cervical cancer (β = 0.16), reported an annual income less than $50,000 (β = 0.13), or were a former smoker (β = 0.11). Women were more willing to use Device A (mean = 3.72, 67.6% indicated "agree" or "strongly agree"), Device C (mean = 3.86, 73.9% indicated "agree" or "strongly agree"), and Device D (mean = 3.81, 72.1% indicated "agree" or "strongly agree") than Device B (mean = 3.36, 49.4% indicated "agree" or "strongly agree"; all p < 0.05). Acceptability of HPV self-sampling as a cervical cancer screening strategy is generally high among women. Future efforts should consider the potential impact that device type may have on women's use of an HPV self-sample at home.

由于人乳头瘤病毒(HPV)自我抽样在美国继续作为一种潜在的宫颈癌筛查策略出现,有必要检查妇女对这种筛查方法的可接受性。此外,由于存在几种HPV自采样设备,确定女性的偏好是否因设备类型而异是很重要的。我们于2017年秋季对全国范围内21-65岁(宫颈癌筛查的推荐年龄范围)的女性(n = 605)进行了一项在线调查。多变量线性回归确定了妇女在家使用HPV自我样本意愿的相关因素。我们使用重复测量方差分析来确定四种自采样设备的偏好是否不同:Evalyn®Brush(设备A), HerSwab®(设备B), Catch-All®拭子(设备C)和Qvintip®(设备D)。大多数女性愿意在家中使用HPV自采样(平均值= 4.03[可能范围:1-5],标准差= 1.09,72.7%表示“可能愿意”或“肯定愿意”)。自采样最常见的问题是测试准确性(53.1%)和获取样本不正确(51.1%)。如果女性报告宫颈癌的严重程度较高(β = 0.16),报告年收入低于50,000美元(β = 0.13),或者曾经吸烟(β = 0.11),则更愿意在家中使用HPV自我样本。女性更愿意使用设备A(平均= 3.72,67.6%表示“同意”或“非常同意”)、设备C(平均= 3.86,73.9%表示“同意”或“非常同意”)和设备D(平均= 3.81,72.1%表示“同意”或“非常同意”),而设备B(平均= 3.36,49.4%表示“同意”或“非常同意”);所有p
{"title":"Acceptability of Human Papillomavirus Self-Sampling Among a National Sample of Women in the United States.","authors":"Erin Bishop,&nbsp;Mira L Katz,&nbsp;Paul L Reiter","doi":"10.1089/biores.2018.0040","DOIUrl":"https://doi.org/10.1089/biores.2018.0040","url":null,"abstract":"<p><p>As human papillomavirus (HPV) self-sampling continues to emerge as a potential cervical cancer screening strategy in the United States, it is necessary to examine women's acceptability of this screening approach. Furthermore, since several HPV self-sampling devices exist, it is important to determine if women's preferences differ by device type. We conducted an online survey in Fall 2017 with a national sample of women (<i>n</i> = 605) ages 21-65 years (the recommended age range for cervical cancer screening). Multivariable linear regression identified correlates of women's willingness to use an HPV self-sample at home. We used repeated measures analysis of variance to determine if preferences differed across four self-sampling devices: Evalyn<sup>®</sup> Brush (Device A), HerSwab<sup>®</sup> (Device B), Catch-All<sup>®</sup> Swab (Device C), and Qvintip<sup>®</sup> (Device D). Most women were willing to use an HPV self-sample at home (mean = 4.03 [possible range: 1-5], standard deviation = 1.09, 72.7% indicated \"probably willing\" or \"definitely willing\"). The most common concerns about self-sampling were related to test accuracy (53.1%) and obtaining the sample incorrectly (51.1%). Women were more willing to use an HPV self-sample at home if they reported greater perceived severity of cervical cancer (<i>β</i> = 0.16), reported an annual income less than $50,000 (<i>β</i> = 0.13), or were a former smoker (<i>β</i> = 0.11). Women were more willing to use Device A (mean = 3.72, 67.6% indicated \"agree\" or \"strongly agree\"), Device C (mean = 3.86, 73.9% indicated \"agree\" or \"strongly agree\"), and Device D (mean = 3.81, 72.1% indicated \"agree\" or \"strongly agree\") than Device B (mean = 3.36, 49.4% indicated \"agree\" or \"strongly agree\"; all <i>p</i> < 0.05). Acceptability of HPV self-sampling as a cervical cancer screening strategy is generally high among women. Future efforts should consider the potential impact that device type may have on women's use of an HPV self-sample at home.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/biores.2018.0040","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37214240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Electroporation: A Sustainable and Cell Biology Preserving Cell Labeling Method for Adipogenous Mesenchymal Stem Cells. 电穿孔:一种可持续的、保存细胞生物学的脂肪性间充质干细胞标记方法。
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-03-29 DOI: 10.1089/biores.2019.0001
Kathrin von der Haar, Rebecca Jonczyk, Antonina Lavrentieva, Birgit Weyand, Peter Vogt, André Jochums, Frank Stahl, Thomas Scheper, Cornelia A Blume

Human mesenchymal stem cells derived from adipose tissue (AD-hMSCs) represent a promising source for tissue engineering and are already widely used in cell therapeutic clinical trials. Until today, an efficient and sustainable cell labeling system for cell tracking does not exist. We evaluated transient transfection through electroporation for cell labeling and compared it with lentiviral transduction for AD-hMSCs. In addition, we tested whether nonsense DNA or a reporter gene such as enhanced green fluorescent protein (EGFP) is the more suitable label for AD-hMSCs. Using electroporation, the transfection efficiency reached a maximal level of 44.6 ± 1.1% EGFP-positive cells after selective and expansive cultivation of the mixed MSC population, and was 44.5 ± 1.4% after gene transfer with Cyanin3-marked nonsense-label DNA, which remained stable during 2 weeks of nonselective cultivation (37.2 ± 4.7% positive AD-hMSCs). Electroporation with both nonsense DNA and pEGFP-N1 led to a slight growth retardation of 45.2% and 59.1%, respectively. EGFP-transfected or transduced AD-hMSCs showed a limited adipogenic and osteogenic differentiation capacity, whereas it was almost unaffected in cells electroporated with the nonsense-label DNA. The nonsense DNA was detectable through quantitative real-time polymerase chain reaction for at least 5 weeks/10 passages and in differentiated AD-hMSCs. EGFP-labeled cells were trackable for 24 h in vitro and served as testing cells with new materials for dental implants for 7 days. In contrast, lentivirally transduced AD-hMSCs showed an altered natural immune phenotype of the AD-hMSCs with lowered expression of two cell type defining surface markers (CD44 and CD73) and a relevantly decreased cell growth by 71.8% as assessed by the number of colony-forming units. We suggest electroporation with nonsense DNA as an efficient and long-lasting labeling method for AD-hMSCs with the comparably lowest negative impact on the phenotype or the differentiation capacity of the cells, which may, therefore, be suitable for tissue engineering. In contrast, EGFP transfection by electroporation is efficient but may be more suitable for cell tracking within cell therapies without MSC differentiation procedures. Since current protocols of lentiviral gene transduction include the risk of cell biological alterations, electroporation seems advantageous and sustainable enough for hMSC labeling.

来源于脂肪组织的人间充质干细胞(AD-hMSCs)是组织工程的一个很有前途的来源,并且已经广泛用于细胞治疗临床试验。直到今天,用于细胞追踪的高效和可持续的细胞标记系统还不存在。我们评估了通过电穿孔进行细胞标记的瞬时转染,并将其与AD hMSCs的慢病毒转导进行了比较。此外,我们测试了无义DNA或报告基因(如增强型绿色荧光蛋白(EGFP))是否是AD hMSCs更合适的标记。使用电穿孔,转染效率达到44.6的最大水平 ± 混合MSC群体的选择性和扩大培养后,1.1%的EGFP阳性细胞,为44.5 ± 用Cyani3标记的无义标记DNA进行基因转移后1.4%,该标记DNA在2周的非选择性培养中保持稳定(37.2 ± 4.7%阳性AD-hMSC)。用无义DNA和pEGFP-N1电穿孔分别导致45.2%和59.1%的轻微生长迟缓。EGFP转染或转导的AD hMSCs显示出有限的成脂和成骨分化能力,而在用无义标记DNA电穿孔的细胞中几乎不受影响。无义DNA可通过定量实时聚合酶链反应检测至少5周/10代,并在分化的AD hMSCs中检测到。EGFP标记的细胞可追踪24 h,并用新材料作为测试细胞用于种植牙7天。相反,慢病毒转导的AD hMSC显示出AD hMSC的自然免疫表型改变,两种细胞类型定义表面标记物(CD44和CD73)的表达降低,并且通过集落形成单位的数量评估,细胞生长相应地降低了71.8%。我们建议用无义DNA电穿孔作为AD hMSCs的一种有效和持久的标记方法,对细胞的表型或分化能力的负面影响相对最低,因此,这可能适用于组织工程。相反,通过电穿孔的EGFP转染是有效的,但可能更适合在没有MSC分化程序的细胞治疗中进行细胞追踪。由于目前慢病毒基因转导的方案包括细胞生物学改变的风险,电穿孔似乎对hMSC标记足够有利和可持续。
{"title":"Electroporation: A Sustainable and Cell Biology Preserving Cell Labeling Method for Adipogenous Mesenchymal Stem Cells.","authors":"Kathrin von der Haar,&nbsp;Rebecca Jonczyk,&nbsp;Antonina Lavrentieva,&nbsp;Birgit Weyand,&nbsp;Peter Vogt,&nbsp;André Jochums,&nbsp;Frank Stahl,&nbsp;Thomas Scheper,&nbsp;Cornelia A Blume","doi":"10.1089/biores.2019.0001","DOIUrl":"10.1089/biores.2019.0001","url":null,"abstract":"<p><p>Human mesenchymal stem cells derived from adipose tissue (AD-hMSCs) represent a promising source for tissue engineering and are already widely used in cell therapeutic clinical trials. Until today, an efficient and sustainable cell labeling system for cell tracking does not exist. We evaluated transient transfection through electroporation for cell labeling and compared it with lentiviral transduction for AD-hMSCs. In addition, we tested whether nonsense DNA or a reporter gene such as enhanced green fluorescent protein (EGFP) is the more suitable label for AD-hMSCs. Using electroporation, the transfection efficiency reached a maximal level of 44.6 ± 1.1% EGFP-positive cells after selective and expansive cultivation of the mixed MSC population, and was 44.5 ± 1.4% after gene transfer with Cyanin3-marked nonsense-label DNA, which remained stable during 2 weeks of nonselective cultivation (37.2 ± 4.7% positive AD-hMSCs). Electroporation with both nonsense DNA and pEGFP-N1 led to a slight growth retardation of 45.2% and 59.1%, respectively. EGFP-transfected or transduced AD-hMSCs showed a limited adipogenic and osteogenic differentiation capacity, whereas it was almost unaffected in cells electroporated with the nonsense-label DNA. The nonsense DNA was detectable through quantitative real-time polymerase chain reaction for at least 5 weeks/10 passages and in differentiated AD-hMSCs. EGFP-labeled cells were trackable for 24 h <i>in vitro</i> and served as testing cells with new materials for dental implants for 7 days. In contrast, lentivirally transduced AD-hMSCs showed an altered natural immune phenotype of the AD-hMSCs with lowered expression of two cell type defining surface markers (CD44 and CD73) and a relevantly decreased cell growth by 71.8% as assessed by the number of colony-forming units. We suggest electroporation with nonsense DNA as an efficient and long-lasting labeling method for AD-hMSCs with the comparably lowest negative impact on the phenotype or the differentiation capacity of the cells, which may, therefore, be suitable for tissue engineering. In contrast, EGFP transfection by electroporation is efficient but may be more suitable for cell tracking within cell therapies without MSC differentiation procedures. Since current protocols of lentiviral gene transduction include the risk of cell biological alterations, electroporation seems advantageous and sustainable enough for hMSC labeling.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/biores.2019.0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37293591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
After Gestational Diabetes: Impact of Pregnancy Interval on Recurrence and Type 2 Diabetes. 妊娠糖尿病后:妊娠间隔对复发和 2 型糖尿病的影响。
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-03-25 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2018.0043
Judith Bernstein, Aviva Lee-Parritz, Emily Quinn, Omid Ameli, Myrita Craig, Timothy Heeren, Ronald Iverson, Brian Jack, Lois McCloskey

The contribution of pregnancy interval after gestational diabetes (GDM) to type 2 diabetes (T2DM) onset is a poorly understood but potentially modifiable factor for T2DM prevention. The purpose of this study was to assess the impact of GDM recurrence and/or delivery interval on follow-up care and T2DM onset in a sample of continuously insured women with a term livebirth within 3 years of a GDM-affected delivery. This is a secondary analysis of a cohort of 12,622 women with GDM, 2006-2012, drawn from a national administrative data system (OptumLabs Data Warehouse). We followed 1091 women with GDM who had a subsequent delivery within 3 years of their index delivery. GDM recurred in 49.3% of subsequent pregnancies regardless of the interval to the next conception. Recurrence tripled the odds of early T2DM onset within 3 years of the second delivery. Women with GDM recurrence had greater likelihood of glucose testing in that 3-year interval, but not transition to primary care for continued monitoring, as required by both American Congress of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) guidelines. In multivariable analysis, we found a trend toward increased likelihood of T2DM onset for short interpregnancy intervals (≤1 year vs. 3 year, 0.08). Pregnancy interval may play a previously unrecognized role in progression to T2DM. T2DM onset after GDM can be prevented or mitigated, but many women in even this insured sample did not receive recommended follow-up monitoring and preventive care, even after a GDM recurrence. The postpartum visit may be an ideal time to inform patients about T2DM prevention opportunities, and discuss potential benefits of optimal spacing of future pregnancies.

妊娠期糖尿病(GDM)后的妊娠间隔对 2 型糖尿病(T2DM)发病的影响鲜为人知,但却是预防 T2DM 的潜在可调节因素。本研究的目的是评估妊娠期糖尿病复发和/或分娩间隔对后续护理和 T2DM 发病的影响,研究对象是受妊娠期糖尿病影响的分娩后 3 年内足月活产的连续参保妇女。这是一项对 2006-2012 年期间 12622 名 GDM 妇女队列的二次分析,数据来源于国家行政数据系统(OptumLabs 数据仓库)。我们对 1091 名在初次分娩后 3 年内再次分娩的 GDM 妇女进行了跟踪调查。在49.3%的后续妊娠中,无论间隔多久再孕,GDM都会复发。复发是第二次分娩后 3 年内 T2DM 早期发病几率的三倍。GDM复发的妇女更有可能在3年内接受血糖检测,但不会按照美国妇产科医师协会(ACOG)和美国糖尿病协会(ADA)指南的要求转到初级保健机构继续接受监测。在多变量分析中,我们发现妊娠间隔越短(≤1 年 vs. 3 年,0.08),T2DM 发病的可能性越大。怀孕间隔可能在 T2DM 的发展过程中起到了以前未曾认识到的作用。GDM 后 T2DM 的发生是可以预防或减轻的,但即使是在这一保险样本中,许多妇女也没有接受建议的随访监测和预防护理,即使在 GDM 复发后也是如此。产后访视可能是告知患者预防 T2DM 的机会,并讨论未来最佳怀孕间隔的潜在益处的理想时机。
{"title":"After Gestational Diabetes: Impact of Pregnancy Interval on Recurrence and Type 2 Diabetes.","authors":"Judith Bernstein, Aviva Lee-Parritz, Emily Quinn, Omid Ameli, Myrita Craig, Timothy Heeren, Ronald Iverson, Brian Jack, Lois McCloskey","doi":"10.1089/biores.2018.0043","DOIUrl":"10.1089/biores.2018.0043","url":null,"abstract":"<p><p>The contribution of pregnancy interval after gestational diabetes (GDM) to type 2 diabetes (T2DM) onset is a poorly understood but potentially modifiable factor for T2DM prevention. The purpose of this study was to assess the impact of GDM recurrence and/or delivery interval on follow-up care and T2DM onset in a sample of continuously insured women with a term livebirth within 3 years of a GDM-affected delivery. This is a secondary analysis of a cohort of 12,622 women with GDM, 2006-2012, drawn from a national administrative data system (OptumLabs Data Warehouse). We followed 1091 women with GDM who had a subsequent delivery within 3 years of their index delivery. GDM recurred in 49.3% of subsequent pregnancies regardless of the interval to the next conception. Recurrence tripled the odds of early T2DM onset within 3 years of the second delivery. Women with GDM recurrence had greater likelihood of glucose testing in that 3-year interval, but not transition to primary care for continued monitoring, as required by both American Congress of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) guidelines. In multivariable analysis, we found a trend toward increased likelihood of T2DM onset for short interpregnancy intervals (≤1 year vs. 3 year, 0.08). Pregnancy interval may play a previously unrecognized role in progression to T2DM. T2DM onset after GDM can be prevented or mitigated, but many women in even this insured sample did not receive recommended follow-up monitoring and preventive care, even after a GDM recurrence. The postpartum visit may be an ideal time to inform patients about T2DM prevention opportunities, and discuss potential benefits of optimal spacing of future pregnancies.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37100353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications. 诱导多能干细胞技术在美国、日本和欧洲的专利申请趋势。
Q2 Biochemistry, Genetics and Molecular Biology Pub Date : 2019-03-19 eCollection Date: 2019-01-01 DOI: 10.1089/biores.2018.0028
Yasushi Morita, Hanayuki Okura, Akifumi Matsuyama

Patent application trends were investigated for induced pluripotent stem cell (iPSC) technologies, particularly disease-specific cell technologies related to iPSCs, in the U.S., Japanese, and European applications during 2017. The number of patent applications for iPSC technologies was 1516 in the United States, 895 in Japan, and 420 in Europe, with 5% of applications for disease-specific cell technologies. In contrast, the percentages of patent applications for iPSC preparation and differentiation technologies were 17% and 23%, respectively. Patent applications for disease-specific cell technologies were classified into four technical fields and 14 disorder groups. In the technical fields, patent applications for genetically engineered cell technologies were prominent, accounting for 63%, 50%, and 65% of the U.S., Japanese, and European applications for 11, 8, and 7 disorder groups, respectively. In the disorder groups, the percentages of patent applications for neurological disorders were 40%, 32%, and 40% of the U.S., Japanese, and European applications, respectively, which were filed in four technical fields in the U.S. and Japanese applications. The U.S. patent applications for disease-specific cell technologies were filed by applicants in the United States, Japan, France, Belgium, Italy, Korea, and Canada; however, patent applications filed by those in Belgium, Italy, and Canada were not found in the Japanese and European applications. The percentages of patent applications filed by the U.S. applicants were 72%, 55%, and 65% of the U.S., Japanese, and European applications, respectively. Most patent applications filed by the U.S. applicants were in the field of genetically engineered cells for 11 disorder groups, which mostly included neurological and blood disorders. Japanese applicants mainly filed patent applications for drug screening technologies; subjects included five disorder groups, particularly neurological and bone/articular disorders. French applicants filed patent applications for neurological disorders in the field of genetically engineered cells and drug screening technologies. Korean applicants filed patent applications for patient-derived cell technologies for neurological, metabolic, and chromosomal/genetic disorders. In conclusion, more than half of patent applications were for genetically engineered cells for 11 disorders, most of which were filed by U.S. applicants.

2017年,在美国、日本和欧洲,研究了诱导多能干细胞(iPSC)技术的专利申请趋势,特别是与iPSC相关的疾病特异性细胞技术。iPSC技术的专利申请数量在美国为1516件,在日本为895件,在欧洲为420件,其中5%的申请是针对特定疾病的细胞技术。相比之下,iPSC制备技术和分化技术的专利申请比例分别为17%和23%。疾病特异性细胞技术的专利申请被分为四个技术领域和14个疾病组。在技术领域,基因工程细胞技术的专利申请量突出,分别占美国、日本、欧洲11种、8种、7种疾病申请量的63%、50%、65%。在障碍组中,在美国、日本和欧洲的申请中,神经障碍的专利申请比例分别为40%、32%和40%,这些申请分别在美国和日本的四个技术领域提出。疾病特异性细胞技术的美国专利申请是由美国、日本、法国、比利时、意大利、韩国和加拿大的申请人提交的;但是,在日本和欧洲的申请中没有发现比利时、意大利和加拿大的专利申请。美国申请人提交的专利申请比例分别为美国、日本和欧洲申请的72%、55%和65%。美国申请人提交的大多数专利申请都是针对11种疾病的基因工程细胞领域,其中主要包括神经和血液疾病。日本申请人主要提交了药物筛选技术方面的专利申请;受试者包括五组疾病,特别是神经和骨/关节疾病。法国申请人提交了基因工程细胞和药物筛选技术领域的神经疾病专利申请。韩国申请人申请了用于神经、代谢和染色体/遗传疾病的患者衍生细胞技术的专利。总之,超过一半的专利申请是针对11种疾病的基因工程细胞,其中大部分是由美国申请人提交的。
{"title":"Patent Application Trends of Induced Pluripotent Stem Cell Technologies in the United States, Japanese, and European Applications.","authors":"Yasushi Morita,&nbsp;Hanayuki Okura,&nbsp;Akifumi Matsuyama","doi":"10.1089/biores.2018.0028","DOIUrl":"https://doi.org/10.1089/biores.2018.0028","url":null,"abstract":"<p><p>Patent application trends were investigated for induced pluripotent stem cell (iPSC) technologies, particularly disease-specific cell technologies related to iPSCs, in the U.S., Japanese, and European applications during 2017. The number of patent applications for iPSC technologies was 1516 in the United States, 895 in Japan, and 420 in Europe, with 5% of applications for disease-specific cell technologies. In contrast, the percentages of patent applications for iPSC preparation and differentiation technologies were 17% and 23%, respectively. Patent applications for disease-specific cell technologies were classified into four technical fields and 14 disorder groups. In the technical fields, patent applications for genetically engineered cell technologies were prominent, accounting for 63%, 50%, and 65% of the U.S., Japanese, and European applications for 11, 8, and 7 disorder groups, respectively. In the disorder groups, the percentages of patent applications for neurological disorders were 40%, 32%, and 40% of the U.S., Japanese, and European applications, respectively, which were filed in four technical fields in the U.S. and Japanese applications. The U.S. patent applications for disease-specific cell technologies were filed by applicants in the United States, Japan, France, Belgium, Italy, Korea, and Canada; however, patent applications filed by those in Belgium, Italy, and Canada were not found in the Japanese and European applications. The percentages of patent applications filed by the U.S. applicants were 72%, 55%, and 65% of the U.S., Japanese, and European applications, respectively. Most patent applications filed by the U.S. applicants were in the field of genetically engineered cells for 11 disorder groups, which mostly included neurological and blood disorders. Japanese applicants mainly filed patent applications for drug screening technologies; subjects included five disorder groups, particularly neurological and bone/articular disorders. French applicants filed patent applications for neurological disorders in the field of genetically engineered cells and drug screening technologies. Korean applicants filed patent applications for patient-derived cell technologies for neurological, metabolic, and chromosomal/genetic disorders. In conclusion, more than half of patent applications were for genetically engineered cells for 11 disorders, most of which were filed by U.S. applicants.</p>","PeriodicalId":9100,"journal":{"name":"BioResearch Open Access","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/biores.2018.0028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37086833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
BioResearch Open Access
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1